Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma.

@article{Keating2010RituximabAR,
  title={Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma.},
  author={Gillian M. Keating},
  journal={Drugs},
  year={2010},
  volume={70 11},
  pages={1445-76}
}
Rituximab (MabThera, Rituxan) is a chimeric mouse anti-human CD20 monoclonal antibody. This article reviews the use of intravenous rituximab in the treatment of chronic lymphocytic leukaemia (CLL), low-grade or follicular lymphoma, and diffuse large B-cell lymphoma. The addition of rituximab to fludarabine plus cyclophosphamide significantly prolonged progression-free survival both in previously untreated patients with CLL and in those with relapsed or refractory CLL, according to the results… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 67 extracted citations

Similar Papers

Loading similar papers…